RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Amyloid-beta peptide is central to the pathology of Alzheimer's disease, because it is neurotoxic--directly by inducing oxidant stress, and indirectly by activating microglia. A specific cell-surface acceptor site that could focus its effects on target cells has been postulated but not identified. Here we present evidence that the 'receptor for advanced glycation end products' (RAGE) is such a receptor, and that it mediates effects of the peptide on neurons and microglia. Increased expressing of RAGE in Alzheimer's disease brain indicates that it is relevant to the pathogenesis of neuronal dysfunction and death.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Yan et al. reported that Aβ peptides and Aβ oligomers can bind to RAGE receptor and activate glial cells.331”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [331]
In the citing paper
“Given that intracellular A β overload can induce oxidative stress and cell death [ 38-40 ]”
From Restores Aβ Clearance by Overcoming PCSK9–LRP1 Dysregulation and TRIB3‐Mediated Autophagy Blockade in Alzheimer's Disease (2026) · cites this paper as [38]
In the citing paper
“Enhancing A β uptake or efflux alone may increase intracellular A β -handling burden if autophagic degradation remains impaired [ 38-40 ].”
From Restores Aβ Clearance by Overcoming PCSK9–LRP1 Dysregulation and TRIB3‐Mediated Autophagy Blockade in Alzheimer's Disease (2026) · cites this paper as [38]
In the citing paper
“Apolipoprotein E3 (ApoE3), another key component of the lipoprotein‐like nanostructure, acts as an effective anti‐inflammatory molecule.[ 18 ]”
From Multifunctional Nanostructure RAP‐RL Rescues Alzheimer's Cognitive Deficits through Remodeling the Neurovascular Unit (2021) · cites this paper as [18]
In the citing paper
“In addition, a key component of RAP‐RL, ApoE3, has been shown to regulate pericyte‐mediated cerebrovascular integrity and anti‐inflammatory reaction.[ 18 , 19 ]”
From Multifunctional Nanostructure RAP‐RL Rescues Alzheimer's Cognitive Deficits through Remodeling the Neurovascular Unit (2021) · cites this paper as [18]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Hydrogen peroxide mediates amyloid β protein toxicity
Behl, C. (1994) · Cell · doi:10.1016/0092-8674(94)90131-7 · Cited by 2,074
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
Osborn, L., Hession, C., Tizard, R., Vassallo, C., Luhowskyj, S., Chi-Rosso, G., & Lobb, R. (1989) · Cell · doi:10.1016/0092-8674(89)90775-7 · Cited by 1,689
Neeper, M., Schmidt, A. M., Brett, J., Yan, S. D., Wang, F., Pan, Y. C., Elliston, K., Stern, D., & Shaw, A. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42138-2 · Cited by 1,541
Self-citationNeurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state
Pike, C., Burdick, D., Walencewicz, A., Glabe, C., & Cotman, C. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-04-01676.1993 · Cited by 1,417
Activation of microglial cells by β-amyloid protein and interferon-γ
Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., & Rossi, F. (1995) · Nature · doi:10.1038/374647a0 · Cited by 1,314
Yan, S. D., Schmidt, A. M., Anderson, G. M., Zhang, J., Brett, J., Zou, Y. S., Pinsky, D., & Stern, D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36966-1 · Cited by 1,306
Self-citationThe Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin
Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., Nagashima, M., Lundh, E. R., Vijay, S., Nitecki, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25752 · Cited by 1,151
Self-citationHensley, K., Carney, J. M., Mattson, M. P., Aksenova, M., Harris, M., Wu, J. F., Floyd, R. A., & Butterfield, D. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3270 · Cited by 1,086
Research works printed but not linked: 4
- Haass, C. & Selkoe, D. Cell 7, 1039–1042 (1994).
- Trojanowski, J. & Lee, V. Am. J. Pathol. 144, 449–453 (1994).
- Gumkowski, F. et al. Blood Vessels 24, 11–18 (1987).
- Brett, J. et al. Am. J. Pathol. 143, 1699–1712 (1993).
Cited by
Items 501–600 of 1,027
Adaptive immunity after cell death
Zelenay, S., & Sousa, C. R. E. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.03.005 · Cited by 138
Sasahira, T., Akama, Y., Fujii, K., & Kuniyasu, H. (2005) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-005-1210-x · Cited by 124
Ionic effects of the Alzheimer's disease β-amyloid precursor protein and its metabolic fragments
Fraser, S. P., Suh, Y.-H., & Djamgoz, M. B. A. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10079-5 · Cited by 135
Husemann, J., Loike, J. D., Kodama, T., & Silverstein, S. C. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00239-9 · Cited by 131
“…(Krieger and Herz, 1994), SR-BI findings of Huang et al. (1999), that mice genetically(Buechler et al., 1999), CD36 (Huh et al., 1996), RAGE 2 / 2(Yan et al., 1996), LRP (Krieger and Herz, 1994)), that deficient in SR-A (SR-A ) and expressing a transgene mediate interactions of human, rat and…”
BackgroundBiomarkers in Alzheimer's disease drug development
Cummings, J. L. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.06.004 · Cited by 121
“RAGE is overexpressed in AD suggesting that increased Ab transport into the brain may contribute to the amyloid pathology [42].”
BackgroundTargeted reduction of advanced glycation improves renal function in obesity
Harcourt, B. E., Sourris, K. C., Coughlan, M. T., Walker, K. Z., Dougherty, S. L., Andrikopoulos, S., Morley, A. L., Thallas‐Bonke, V., Chand, V., Penfold, S. A., et al. (2011) · Kidney International · doi:10.1038/ki.2011.57 · Cited by 123
Hyperoxia sensing: From molecular mechanisms to significance in disease
Gore, A., Muralidhar, M., Espey, M. G., Degenhardt, K., & Mantell, L. L. (2010) · Journal of Immunotoxicology · doi:10.3109/1547691x.2010.492254 · Cited by 127
“RAGE is a multi-ligand receptor that binds to several ligands including AGE, amphoterins (high-mobility group protein-1), S100/calgranulins, amyloid-β peptide, β-fibrils, and Mac-1 (Neeper et al., 1992; Hori et al., 1995; Yan et al., 1996; Hofmann et al., 1999).”
BackgroundA Novel Presenilin‐2 Splice Variant in Human Alzheimer's Disease Brain Tissue
Sato, N., Hori, O., Yamaguchi, A., Lambert, J., Chartier‐Harlin, M., Robinson, P. A., Delacourte, A., Schmidt, A. M., Furuyama, T., Imaizumi, K., et al. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0722498.x · Cited by 122
“The ligation of cellular RAGE by amyloid-b-peptide resulted in increased oxidant stress and associated cell death (Yan et al., 1996).”
BackgroundSelf-citationCurrent therapeutic targets for the treatment of Alzheimer’s disease
Grill, J. D., & Cummings, J. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.29 · Cited by 121
Accumulation of intraneuronal Aβ correlates with ApoE4 genotype
Christensen, D. Z., Schneider-Axmann, T., Lucassen, P. J., Bayer, T. A., & Wirths, O. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0666-1 · Cited by 120
Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal Transduction
Manigrasso, M. B., Pan, J., Rai, V., Zhang, J., Reverdatto, S., Quadri, N., DeVita, R. J., Ramasamy, R., Shekhtman, A., & Schmidt, A. M. (2016) · Scientific Reports · doi:10.1038/srep22450 · Cited by 120
Self-citationThe role of innate immunity in Alzheimer's disease
Ennerfelt, H. E., & Lukens, J. R. (2020) · Immunological Reviews · doi:10.1111/imr.12896 · Cited by 119
Dual roles for HMGB1: DNA binding and cytokine
Czura, C. J., Wang, H., & Tracey, K. J. (2001) · Journal of Endotoxin Research · doi:10.1177/09680519010070041401 · Cited by 121
Pillot, T., Drouet, B., Queillé, S., Labeur, C., Vandekerckhove, J., Rosseneu, M., Pinçon‐Raymond, M., & Chambaz, J. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0731626.x · Cited by 120
Role of ERAB/l-3-Hydroxyacyl-coenzyme A Dehydrogenase Type II Activity in Aβ-induced Cytotoxicity
Du Yan, S., Shi, Y., Zhu, A., Fu, J., Zhu, H., Zhu, Y., Gibson, L., Stern, E., Collison, K., Al-Mohanna, F., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.4.2145 · Cited by 120
Self-citationNakanishi, H., Zhang, J., Koike, M., Nishioku, T., Okamoto, Y., Kominami, E., von Figura, K., Peters, C., Yamamoto, K., Saftig, P., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07526.2001 · Cited by 120
“These activated microglia appear to be directly involved in propagation of neuropathological events such as Alzheimer’s disease because the microglial activation leads to produce mediators of inflammation-mediated neurodegeneration including nitric oxide (NO) and tumor necrosis factor- (TNF-) (Meda et al., 1995; Brown…”
BackgroundInfluentialCognitive dysfunction: a growing link between diabetes and Alzheimer’s disease
Jash, K., Gondaliya, P., Kirave, P., Kulkarni, B., Sunkaria, A., & Kalia, K. (2020) · Drug Development Research · doi:10.1002/ddr.21579 · Cited by 119
“Receptor for AGE (RAGE) which act as a site for AGE-binding are present in neuron-derived exosomes and were found to be involved in the pathogenesis of AD (Patterson, Deep, & Brinkley, 2018; Yan et al., 1996).”
BackgroundThe Role of HMGB1 in the Pathogenesis of Type 2 Diabetes
Wang, Y., Zhong, J., Zhang, X., Liu, Z., Yang, Y., Gong, Q., & Ren, B. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2543268 · Cited by 129
“Recent advances implicated that HMGB1 had alarming activities via activating proinflammatory responses after being passively released by necrotic cells or actively secreted by activated immune cells into the extracellular milieu [13, 14].”
BackgroundEvaluation of rage isoforms, ligands, and signaling in the brain
Ding, Q., & Keller, J. N. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2005.08.006 · Cited by 119
Poon, H. F., Joshi, G., Sultana, R., Farr, S. A., Banks, W. A., Morley, J. E., Calabrese, V., & Butterfield, D. A. (2004) · Brain Research · doi:10.1016/j.brainres.2004.05.048 · Cited by 127
“Another Ah-mediated reactive oxygen species (ROS) production is through its binding to the receptor of advance glycated end-products (RAGE) [109].”
BackgroundMicrobial involvement in Alzheimer disease development and progression
Bulgart, H. R., Neczypor, E. W., Wold, L. E., & Mackos, A. R. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00378-4 · Cited by 116
Only amyloidogenic intermediates of transthyretin induce apoptosis
Andersson, K., Olofsson, A., Nielsen, E. H., Svehag, S., & Lundgren, E. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00465-5 · Cited by 139
Murphy, G. M., Yang, L., & Cordell, B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.33.20967 · Cited by 118
The Many Faces of Astrocytes in Alzheimer's Disease
Monterey, M. D., Wei, H., Wu, X., & Wu, J. Q. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.619626 · Cited by 117
Synaptic Dysfunction in Alzheimer’s Disease: Aβ, Tau, and Epigenetic Alterations
Li, K., Wei, Q., Liu, F., Hu, F., Xie, A., Zhu, L., & Liu, D. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0533-3 · Cited by 142
Monden, M., Koyama, H., Otsuka, Y., Morioka, T., Mori, K., Shoji, T., Mima, Y., Motoyama, K., Fukumoto, S., Shioi, A., et al. (2012) · Diabetes · doi:10.2337/db11-1116 · Cited by 130
Cecchi, C., & Stefani, M. (2013) · Biophysical Chemistry · doi:10.1016/j.bpc.2013.06.003 · Cited by 124
Potapov, A., Yau, W., Ghirlando, R., Thurber, K. R., & Tycko, R. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b04843 · Cited by 125
Alternative splicing of the murine receptor for advanced glycation end‐products (RAGE) gene
Kalea, A. Z., Reiniger, N., Yang, H., Arriero, M., Schmidt, A. M., & Hudson, B. I. (2009) · The FASEB Journal · doi:10.1096/fj.08-117739 · Cited by 116
Self-citationBiological activity and pathological implications of misfolded proteins
Bellotti, V., Mangione, P. P., & Stoppini, M. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050348 · Cited by 127
Aβ1–42 reduces P-glycoprotein in the blood–brain barrier through RAGE–NF-κB signaling
Park, R., Kook, S.-Y., Park, J.-C., & Mook-Jung, I. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.258 · Cited by 114
Li, M., Shang, D.-S., Zhao, W.-D., Tian, L., Li, B., Fang, W.-G., Zhu, L., Man, S.-M., & Chen, Y.-H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803013 · Cited by 116
Early Glycoxidation Damage in Brains from Down's Syndrome
Odetti, P. R., Angelini, G., Dapino, D., Zaccheo, D., Garibaldi, S., Dagna-Bricarelli, F., Piombo, G., Perry, G. L., Smith, M. A., Traverso, N., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8186 · Cited by 118
Pharmacological approaches to mitigate neuroinflammation in Alzheimer’s disease
Uddin, M. S., Kabir, M. T., Mamun, A. A., Barreto, G. E., Rashid, M., Perveen, A., & Ashraf, G. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106479 · Cited by 114
MicroRNAs: pioneering regulators in Alzheimer’s disease pathogenesis, diagnosis, and therapy
Li, Y.-B., Fu, Q., Guo, M., Du, Y., Chen, Y., & Cheng, Y. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03075-8 · Cited by 113
Pluta, R., Furmaga-Jabłońska, W., Maciejewski, R., Ułamek-Kozioł, M., & Jabłoński, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8360-z · Cited by 114
“indirectly by activating microglia cells [93, 97].”
Romero, R. J., Chaiworapongsa, T., Savasan, Z. A., Hussein, Y., Dong, Z., Kusanovic, J. P., Kim, C. J., & Hassan, S. S. (2012) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2011.599083 · Cited by 117
Amyloid-β Production: Major Link Between Oxidative Stress and BACE1
Tamagno, E., Guglielmotto, M., Monteleone, D., & Tabaton, M. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9283-6 · Cited by 125
“The role of RAGE in the pathogenesis of AD has been extensively studied because it also binds Ab (Yan et al. 1996).”
Inflammatory pathogenesis in Alzheimer's disease: biological mechanisms and cognitive sequeli
Gahtan, E., & Overmier, J. B. (1999) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(98)00058-x · Cited by 120
KIM, W., HUDSON, B. I., MOSER, B., GUO, J., RONG, L. L., LU, Y., QU, W., LALLA, E., LERNER, S., CHEN, Y., et al. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1338.063 · Cited by 113
Self-citationAntagonism of RAGE suppresses peripheral nerve regeneration
Rong, L. L., Trojaborg, W., Qu, W., Kostov, K., Yan, S. D., Gooch, C., Szabolcs, M., Hays, A. P., & Schmidt, A. M. (2004) · The FASEB Journal · doi:10.1096/fj.04-1899com · Cited by 113
Self-citationThe structure of S100A12 in a hexameric form and its proposed role in receptor signalling
Moroz, O. V., Antson, A. A., Dodson, E. J., Burrell, H., Grist, S. J., Lloyd, R. M., Maitland, N. J., Dodson, G. G., Wilson, K. S., Lukanidin, E. M., et al. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444901021278 · Cited by 115
“Increased expression of RAGE in Alzheimer's disease brain tissue indicates that it is relevant to the pathogenesis of neuronal disfunction and death (Yan et al., 1996).”
BackgroundReynolds, P. R., Kasteler, S. D., Cosio, M. G., Sturrock, A., Huecksteadt, T., & Hoidal, J. R. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00318.2007 · Cited by 113
Rouhiainen, A., Kuja‐Panula, J., Tumova, S., & Rauvala, H. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-230-8_15 · Cited by 126
RAGE in the pathophysiology of skeletal muscle
Riuzzi, F., Sorci, G., Sagheddu, R., Chiappalupi, S., Salvadori, L., & Donato, R. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12350 · Cited by 111
Habib, L. K., Lee, M. T. C., & Yang, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.132860 · Cited by 111
Klegeris, A., Walker, D. G., & McGeer, P. L. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01229-2 · Cited by 110
Soluble Levels of Receptor for Advanced Glycation Endproducts (sRAGE) and Coronary Artery Disease
Hudson, B. I., Harja, E., Moser, B., & Schmidt, A. M. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000164804.05324.8b · Cited by 112
Self-citationChoi, B.-R., Cho, W.-H., Kim, J., Lee, H. J., Chung, C., Jeon, W. K., & Han, J.-S. (2014) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.147 · Cited by 111
Origlia, N., Bonadonna, C., Rosellini, A., Leznik, E., Arancio, O., Yan, S. S., & Domenici, L. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2127-10.2010 · Cited by 111
“Specific antibodies to RAGE have been described in our previous studies (Yan et al., 1996).”
ResultSelf-citationThe role of neutrophil granule proteins in neuroinflammation and Alzheimer’s disease
Stock, A. J., Kasus-Jacobi, A., & Pereira, H. A. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1284-4 · Cited by 111
The Role of NLRP3 Inflammasome in the Pathogenesis of Traumatic Brain Injury
Irrera, N., Russo, M., Pallio, G., Bitto, A., Mannino, F., Minutoli, L., Altavilla, D., & Squadrito, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176204 · Cited by 106
RAGE and amyloid beta interactions: Atomic force microscopy and molecular modeling
Chaney, M. O., Stine, W. B., Kokjohn, T. A., Kuo, Y.-M., Esh, C., Rahman, A., Luehrs, D. C., Schmidt, A. M., Stern, D., Yan, S. D., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.03.014 · Cited by 108
Self-citationDown Syndrome: Advances in Molecular Biology and the Neurosciences
CAPONE, G. T. (2001) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200102000-00007 · Cited by 110
Enhanced Expression of Receptor for Advanced Glycation End Products in Chronic Kidney Disease
Hou, F. F., Ren, H., Owen, W. F., Guo, Z. J., Chen, P. Y., Schmidt, A. M., Miyata, T., & Zhang, X. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000131526.99506.f7 · Cited by 114
“Supporting this premise, in vitro studies have demonstrated that engagement of RAGE by AGE results in activation of nuclear factor-kappa B (NF- B), and NF- B sites in the RAGE promoter affect ligand-associated upregulation of RAGE (36,37).”
Self-citationThe molecular basis of the prevention of Alzheimer’s disease through healthy nutrition
Steele, M. L., Stuchbury, G., & Münch, G. W. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.06.002 · Cited by 123
Giri, R. K., Selvaraj, S. K., & Kalra, V. K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.5281 · Cited by 110
RAGE: The Beneficial and Deleterious Effects by Diverse Mechanisms of Actions
Han, S.-H., Kim, Y. H., & Mook-Jung, I. (2011) · Molecules and Cells · doi:10.1007/s10059-011-0030-x · Cited by 108
“RAGE-Aβ interaction induces oxidative stress in endothelial and neuronal cells and then activation of the transcription factor NF-κB, which is blocked by the inactivation of RAGE by antiRAGE IgG or soluble RAGE (Yan et al., 1996).”
BackgroundInfluentialThe multiple faces of RAGE – opportunities for therapeutic intervention in aging and chronic disease
Ramasamy, R., Shekhtman, A., & Schmidt, A. M. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1111873 · Cited by 109
Self-citationFotheringham, A. K., Gallo, L. A., Borg, D. J., & Forbes, J. M. (2022) · Nutrients · doi:10.3390/nu14132675 · Cited by 127
Calcium-regulated intramembrane proteolysis of the RAGE receptor
Galichet, A., Weibel, M., & Heizmann, C. W. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.02.163 · Cited by 131
Hypertension, hypertension-clustering factors and Alzheimer's disease
Skoog, I., & Gustafson, D. (2003) · Neurological Research · doi:10.1179/016164103101201986 · Cited by 109
Possible role of NF-κB and p53 in the glutamate-induced pro-apoptotic neuronal pathway
Grilli, M., & Memo, M. (1999) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400463 · Cited by 115
Delineating the Mechanism of Alzheimer’s Disease Aβ Peptide Neurotoxicity
Cappai, R., & Barnham, K. J. (2008) · Neurochemical Research · doi:10.1007/s11064-007-9469-8 · Cited by 108
“The RAGE protein can bind both non-fibrillar and fibrillar Ab and promote Ab’s toxic effects on microglia and neurons [50].”
BackgroundLiu, W., Ma, H., Frost, L., Yuan, T., Dain, J. A., & Seeram, N. P. (2014) · Food Funct. · doi:10.1039/c4fo00538d · Cited by 108
Endothelial Mitochondrial Dysfunction in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
Parodi-Rullán, R., Sone, J. Y., & Fossati, S. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190357 · Cited by 106
Jhamandas, J. H., Wie, M. B., Harris, K., MacTavish, D., & Kar, S. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04111.x · Cited by 108
“ion end products (RAGE) and scavenger receptors are all candidate receptors for the biological actions of this protein (El Khoury et al., 1996; Yan et al., 1996; Kuner et al., 1998; Wang et al., 2000; Jhamandas et al., 2003).”
BackgroundMolecules that Target beta‐Amyloid
Stains, C. I., Mondal, K., & Ghosh, I. (2007) · ChemMedChem · doi:10.1002/cmdc.200700140 · Cited by 125
The role of complement in Alzheimer’s disease pathology
Emmerling, M. R., Watson, M. D., Raby, C. A., & Spiegel, K. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00042-9 · Cited by 117
Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity
Smith, L. M., & Strittmatter, S. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024075 · Cited by 109
High‐Mobility Group Box‐1 and Liver Disease
Gaskell, H., Ge, X., & Nieto, N. (2018) · Hepatology Communications · doi:10.1002/hep4.1223 · Cited by 106
Li, T., Lu, L., Pember, E., Li, X., Zhang, B., & Zhu, Z. (2022) · Cells · doi:10.3390/cells11121925 · Cited by 104
“The blockade of RAGE has shown reduced NF-κB activity, thus RAGE-targeted therapeutics may be applicable in reducing neuroinflammation in AD [41].”
BackgroundSasaki, N., Takeuchi, M., Chowei, H., Kikuchi, S., Hayashi, Y., Nakano, N., Ikeda, H., Yamagishi, S., Kitamoto, T., Saito, T., et al. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00310-5 · Cited by 105
The Receptor for Advanced Glycation End Products Impairs Host Defense in Pneumococcal Pneumonia
van Zoelen, M. A. D., Schouten, M., de Vos, A. F., Florquin, S., Meijers, J. C. M., Nawroth, P. P., Bierhaus, A., & van der Poll, T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801199 · Cited by 106
“The receptor for advanced glycation end products (RAGE)(3) interacts with diverse ligands, such as advanced glycation end products (4), amyloid (5), -sheet fibrils (6), high mobility”
BackgroundSelf-citationThe Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer’s Disease
Hillen, H. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01154 · Cited by 106
“These sticky molecules can bind promiscuously to many proteins and cell surface receptors, e.g., the PrPc protein (Smith and Strittmatter, 2017) or RAGE (Yan et al., 1996).”
BackgroundIribarren, P., Zhou, Y., Hu, J., Le, Y., & Wang, J. M. (2005) · Immunologic Research · doi:10.1385/ir:31:3:165 · Cited by 113
Katsuoka, F., Kawakami, Y., Arai, T., Imuta, H., Fujiwara, M., Kanma, H., & Yamashita, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7263 · Cited by 121
Hindlimb Motor Neurons Require Cu/Zn Superoxide Dismutase for Maintenance of Neuromuscular Junctions
Flood, D. G., Reaume, A. G., Gruner, J. A., Hoffman, E. K., Hirsch, J. D., Lin, Y., Dorfman, K. S., & Scott, R. W. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65162-0 · Cited by 123
Autocrine S100B effects on astrocytes are mediated via RAGE
Ponath, G. D., Schettler, C., Kaestner, F., Voigt, B., WENTKER, D., Arolt, V., & Rothermundt, M. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.12.011 · Cited by 127
Fang, F., Yu, Q., Arancio, O., Chen, D., Gore, S. S., Yan, S. S., & Yan, S. F. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy017 · Cited by 103
Self-citationRoberts, K., Zeineddine, R., Corcoran, L., Li, W., Campbell, I. L., & Yerbury, J. J. (2013) · Glia · doi:10.1002/glia.22444 · Cited by 103
“Scavenger receptors CD36 (Coraci et al., 2002) and SR-A (El Khoury et al., 1996), the receptor for advanced glycation end products (RAGE) (Yan et al., 1996), integrin a6b1integrin and integrin associated CD47 (Bamberger et al., 2003), and CD14 and Toll-like receptors (TLR) 2/4 (ReedGeaghan et al.,…”
BackgroundLitwinoff, E., Hurtado del Pozo, C., Ramasamy, R., & Schmidt, A. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.148 · Cited by 103
Self-citationRAGE Expression in Human T Cells: A Link between Environmental Factors and Adaptive Immune Responses
Akirav, E. M., Preston‐Hurlburt, P., Garyu, J., Henegariu, O., Clynes, R., Schmidt, A. M., & Herold, K. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034698 · Cited by 111
“RAGE activation has been shown to play a role in diverse settings including sepsis and atherosclerosis as well as disease processes including diabetic nephropathy, rheumatoid arthritis, and Alzheimer’s disease and hypoxia/reoxygenase injury [11,18,32,33,34,35,36,37,38,39,40,41,42,43].”
BackgroundSelf-citationKassed, C. A., Willing, A. E., Garbuzova-Davis, S., Sanberg, P. R., & Pennypacker, K. R. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7967 · Cited by 101
Alzheimer’s Disease: Mechanism and Approach to Cell Therapy
Amemori, T., Jendelova, P., Ruzicka, J., Urdzikova, L., & Sykova, E. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125961 · Cited by 102
“During AD progression, the expression of RAGE is upregulated in microglia, neurons and endothelial cells surrounding senile plaques [175].”
BackgroundAlzheimer's disease and chronic periodontitis: Is there an association?
Gaur, S., & Agnihotri, R. (2015) · Geriatrics & Gerontology International · doi:10.1111/ggi.12425 · Cited by 102
Hsieh, H., Schäfer, B. W., Weigle, B., & Heizmann, C. W. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.02.135 · Cited by 118
Choi, Y. J., Chae, S., Kim, J. H., Barald, K. F., Park, J. Y., & Lee, S. (2013) · Scientific Reports · doi:10.1038/srep01921 · Cited by 106
Small heat shock proteins inhibit in vitro Aβ1–42 amyloidogenesis
Kudva, Y. C., Hiddinga, H. J., Butler, P. C., Mueske, C. S., & Eberhardt, N. L. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01180-0 · Cited by 109
Adami, C., Bianchi, R., Pula, G., & Donato, R. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.09.008 · Cited by 101
Combs, C. K., Bates, P., Karlo, J. C., & Landreth, G. E. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00052-3 · Cited by 108
Zhang, J.-X., Xing, J.-G., Wang, L.-L., Jiang, H.-L., Guo, S.-L., & Liu, R. (2017) · Molecules · doi:10.3390/molecules22030334 · Cited by 101
Involvement of maillard reactions in Alzheimer disease
Reddy, V. P., Obrenovich, M. E., Atwood, C., Perry, G. L., & Smith, M. A. (2002) · Neurotoxicity Research · doi:10.1080/1029840290007321 · Cited by 110
Hu, J., & Eldik, L. J. V. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01804-1 · Cited by 114
Chromogranin A Induces a Neurotoxic Phenotype in Brain Microglial Cells
Ciesielski-Treska, J., Ulrich, G., Taupenot, L., Chasserot-Golaz, S., Corti, A., Aunis, D., & Bader, M.-F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14339 · Cited by 101
Transgenic mouse models of Alzheimer’s disease
Janus, C., Chishti, M. A., & Westaway, D. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00033-8 · Cited by 101
Mori, T., Koyama, N., Tan, J., Segawa, T., Maeda, M., & Town, T. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004280 · Cited by 106
The Blood–Brain Barrier in Alzheimer's Disease
Sharma, H. S., Castellani, R. J., Smith, M. A., & Sharma, A. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-386986-9.00003-x · Cited by 111
Ko, S., Lin, Y.-P., Lin, Y.-S., & Chang, S.-S. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.05.005 · Cited by 104
Gridley, K. E., Green, P. S., & Simpkins, J. W. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.5.874 · Cited by 101
“An increasing body of evidence indicates that oxidative damage plays a key role in the pathological events occurring in AD (Good et al., 1996; Yan et al., 1996), with use of antioxidants [i.e., any substance that under physiological conditions significantly delays or inhibits oxidation when present…”
Background
Metadata
- Authors
- Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., Migheli, A., Nawroth, P., Stern, D., & Schmidt, A. M.
- Affiliations
- Columbia University (US)
- University of Turin (IT)
- Heidelberg University (DE)
- Venue
- Nature
- Published
- 1996-08
- Volume
- 382
- Issue
- 6593
- Pages
- 685-691
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2049167261
- Cited by
- 2,012
- References
- 44
- Citations by year
- 2026: 28 · 2025: 33 · 2024: 44 · 2023: 46 · 2022: 56 · 2021: 48 · 2020: 59 · 2019: 58 · 2018: 65 · 2017: 55 · 2016: 77 · 2015: 75 · 2014: 81 · 2013: 93 · 2012: 100
- FWCI
- 58.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- receptor for advanced glycation end products, RAGE, amyloid-beta, neurotoxicity, Alzheimer's disease, microglial activation, oxidative stress, neuronal cell death, cell surface receptors, neuroinflammation
- MeSH terms
- Receptor for Advanced Glycation End Products, Alzheimer Disease, Animals, Base Sequence, Cattle, Cell Line, Cells, Cultured, Endothelium, Vascular, Humans, Molecular Sequence Data, Neurons, Receptors, Immunologic, Biomarkers, Amyloid beta-Peptides, PC12 Cells, Glycation End Products, Advanced, Microglia, DNA Primers, Oxidative Stress, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.